Navigation Links
New regulatory circuit identified for aggressive, malignant brain tumor
Date:4/7/2008

Research using a newly developed algorithm has significantly advanced understanding of the molecular events associated with the most common primary brain tumor in adults, human glioblastoma (GBM). The research, published by Cell Press in the April issue of the journal Cancer Cell, validates known genetic aberrations and identifies events not previously linked with GBM, thereby elucidating new directions for potential therapeutic strategies.

GBM is a devastating neurological cancer that is characterized by widespread invasion, robust angiogenesis and a stubborn resistance to conventional and targeted treatments. Previous research has implicated a long and highly complex list of genes in GBM pathogenesis, emphasizing the need for a systemic prioritization that would separate relevant target genes from bystanders and provide detailed knowledge of the complex interactions between multiple disrupted genes and downstream targets.

Dr. Lynda Chin from Dana-Farber Cancer Institute, Dr. Cameron Brennan from Memorial Sloan-Kettering Cancer Center and their colleagues used a high-resolution genome topography scan (GTS) algorithm to both define and rank the patterns of genomic alterations associated with GBM in primary samples and cell lines. Using this new methodology, the researchers discovered an unanticipated co-deletion pattern among closely related INK genes in the GBM oncogenome.

Specifically, the researchers identified a frequent co-deletion of p18INK4C and p16INK4A, a pattern unique to glioblastoma. Functional reconstitution of p18INK4C in GBM cells lacking both p16INK4A and p18INK4C resulted in impaired cell cycle progression and tumorigenic progression. Depletion of p18INK4C in p16INK4A-deficient primary glial cells or established GBM cells enhanced tumorigenicity while acute suppression of p16INK4A in primary glial cells induced an increase in p18INK4C. These results uncover an unanticipated tumor suppressor role for p18INK4C in human GBM wherein it functions cooperatively with other INK4 family members to constrain inappropriate glial cell proliferation, concludes Dr. Chin.

This study also demonstrates that GTS can address one critical need in the development of a functional map of GBM genetic targets: namely, to prioritize those genomic alterations that are likely to be of importance from among those that are more likely to be bystanders of the cancer process, offers Dr.Brennan. Downstream functional validation of high probability candidates should yield novel GBM genes and potential targets for therapeutic intervention.


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
603-591-8797
Cell Press
Source:Eurekalert

Related medicine news :

1. Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
2. Alsius Corporation Receives Regulatory Approval in China and Mexico
3. InnerPulse, Inc. Appoints Elsa Chi Abruzzo as Vice-President of Regulatory and Quality Affairs
4. CSHL scientists discover new details of a gene-regulatory network governing metabolism
5. Legislative and Regulatory Outlook - 2009 and Beyond for Pharma, Biotech Players
6. Cipher provides CIP-TRAMADOL ER regulatory update
7. Mybank Goes Live With Misys Equation to Support Rapid Growth and Meet Future Regulatory Requirements
8. Mannatech Names New VP of Regulatory Affairs, Quality Assurance
9. Cardiome And Astellas Announce Regulatory Update
10. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
11. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: